Home › Companies › TENX

Tenax Therapeutics

TENX Rare disease Lead: Phase 3 3 Biotech Distilled articles ↓

Cardiovascular Small Molecule

Most recent annual filing: 2026-03-10

Pipeline (2 active programs)

levosimendan

TNX-103

Small Molecule Target: K-ATP channels, troponin C

Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction Phase 3 oral Orion Corporation

imatinib

TNX-201

Small Molecule Target: tyrosine kinase, platelet derived growth factor

Pulmonary Arterial Hypertension Phase 2 oral

Biotech Distilled coverage (3)

Articles open on Substack. Some deep dives are subscriber-only.